Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$224 Mln
P/E Ratio
--
P/B Ratio
11.38
Industry P/E
--
Debt to Equity
0
ROE
-0.01 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-1.75
CFO
$-561.40 Mln
EBITDA
$-481.95 Mln
Net Profit
$19.06 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Merrimack Pharmaceuticals (MACK)
| 12.83 | 2.72 | 2.86 | 21.04 | 33.49 | 28.28 | -6.91 |
|
BSE Sensex*
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Merrimack Pharmaceuticals (MACK)
| 17.02 | 193.09 | -43.25 | 118.73 | 16.73 | -62.14 | -54.64 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
President, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman
Mr. Gary L. Crocker M.B.A.
President, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman
Mr. Gary L. Crocker M.B.A.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Merrimack Pharmaceuticals Inc (MACK) stood at $ 267 Mln as on 31-Mar-24
The share price of Merrimack Pharmaceuticals Inc (MACK) is $15.13 (NASDAQ) as of 28-May-2024 09:30 EDT. Merrimack Pharmaceuticals Inc (MACK) has given a return of 33.49% in the last 3 years.
Merrimack Pharmaceuticals Inc (MACK) has a market capitalisation of $ 224 Mln as on 28-May-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Merrimack Pharmaceuticals Inc (MACK) is 11.38 times as on 28-May-2024, a 395% premium to its peers’ median range of 2.30 times.
Since, TTM earnings of Merrimack Pharmaceuticals Inc (MACK) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Merrimack Pharmaceuticals Inc (MACK) and enter the required number of quantities and click on buy to purchase the shares of Merrimack Pharmaceuticals Inc (MACK).
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
The CEO & director of Mr. Gary L. Crocker M.B.A.. is Merrimack Pharmaceuticals Inc (MACK), and CFO & Sr. VP is Mr. Gary L. Crocker M.B.A..
There is no promoter pledging in Merrimack Pharmaceuticals Inc (MACK).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Merrimack Pharmaceuticals Inc. (MACK) | Ratios |
|---|---|
|
Return on equity(%)
|
-20.41
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-13786.52
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Merrimack Pharmaceuticals Inc (MACK) was $0 Mln.
